The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

December 31, 2013

Conditions
Chronic Renal Failure
Interventions
DRUG

Solution B (balance PD solution)

balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium

DRUG

Solution A (conventional PD solution)

Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)

Trial Locations (7)

Unknown

Centrum Dializ Fresenius Nephrocare, Gdansk

Uniwersytecki Szpital Kliniczny nr 1, Lodz

Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin

Complejo hospitalario universitario de Albacete, Albacete

Fundación Hospital Alcorcón, Madrid

Hospital Universitario Puerta de Hierro, Madrid

Hospital Universitario Ramón y Cajal, Madrid

All Listed Sponsors
lead

Fresenius Medical Care Deutschland GmbH

INDUSTRY

NCT01753154 - The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis | Biotech Hunter | Biotech Hunter